8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Mar 9, 2026·SEC
Biofrontera Inc.(BFRI)Earnings, Financials & Key Ratios
BFRI•NASDAQ
Price updated Jun 19, 2026
AboutBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Show more
- Revenue$42M+11.8%
- EBITDA-$8M+48.4%
- Net Income-$11M+40.7%
- EPS (Diluted)-0.90+72.0%
- Gross Margin78.65%+56.9%
- EBITDA Margin-19.85%+53.9%
- Operating Margin-21.93%+52.5%
- Net Margin-25.26%+46.9%
- ROE-141.3%+63.3%
BFRI Key Insights
Biofrontera Inc. (BFRI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 17.2%
- ✓Trading at only 1.1x book value
- ✓Efficient asset utilization: 1.5x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BFRI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BFRI Price & Volume
Biofrontera Inc. (BFRI) stock price & volume — 10-year historical chart
Loading chart...
BFRI Growth Metrics
Biofrontera Inc. (BFRI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years17.21%
3 Years13.3%
TTM13.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM43.45%
Return on Capital
10 Years-90.56%
5 Years-98.77%
3 Years-118.34%
Last Year-68.4%
BFRI Recent Earnings
Biofrontera Inc. (BFRI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.41-256.5%
$0.12
Rev
$10M-1.6%
$10M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.50+72.4%
$0.29
Rev
$17M+5.9%
$16M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.59+1.7%
$0.60
Rev
$7M-56.7%
$16M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.57-26.7%
$0.45
Rev
$9M-5.4%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.41vs $0.12-256.5% | $10Mvs $10M-1.6% |
| Q2 2026 | Mar 19, 2026 | $0.50vs $0.29+72.4% | $17Mvs $16M+5.9% |
| Q4 2025 | Nov 12, 2025 | $0.59vs $0.60+1.7% | $7Mvs $16M-56.7% |
| Q3 2025 | Aug 13, 2025 | $0.57vs $0.45-26.7% | $9Mvs $10M-5.4% |
Based on last 12 quarters of dataView full earnings history →
BFRI Peer Comparison
Biofrontera Inc. (BFRI) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 DERM | 171.19M | 6.22 | -13.23 | 10.2% | -14.82% | -35.57% | 0.00 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 GDRX | 922.03M | 2.66 | 31.18 | 0.57% | 3.74% | 4.75% | 0.10 | |
 SKIN | 85.9M | 0.66 | -4.14 | -10.02% | -2.03% | -9.41% | 6.20 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 MCK | 90.23B | 750.63 | 19.56 | 12.36% | 1.18% | |||
 CAH | 52.19B | 221.77 | 34.38 | -1.87% | 0.62% |
Compare BFRI vs Peers
Biofrontera Inc. (BFRI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BFRI Income Statement
Biofrontera Inc. (BFRI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 26.18M | 18.85M | 24.1M | 28.67M | 34.07M | 37.3M | 41.7M | 43.2M |
Revenue Growth % | - | -28.01% | 27.86% | 18.98% | 18.82% | 9.49% | 11.8% | 13.7% |
Cost of Goods Sold | 12.41M | 9.07M | 12.74M | 15.19M | 17.44M | 18.61M | 8.9M | 7.44M |
COGS % of Revenue | 47.39% | 48.1% | 52.87% | 52.96% | 51.2% | 49.88% | 21.35% | - |
Gross Profit | 13.77M▲ 0% | 9.78M▼ 29.0% | 11.36M▲ 16.1% | 13.49M▲ 18.8% | 16.63M▲ 23.3% | 18.7M▲ 12.4% | 32.8M▲ 75.5% | 35.77M▲ 0% |
Gross Margin % | 52.61% | 51.9% | 47.13% | 47.04% | 48.8% | 50.12% | 78.65% | 82.79% |
Gross Profit Growth % | - | -28.97% | 16.1% | 18.76% | 23.26% | 12.44% | 75.45% | - |
Operating Expenses | 28.7M | 19.39M | 36.56M | 32.07M | 39.3M | 35.92M | 41.95M | 44.69M |
OpEx % of Revenue | 109.6% | 102.86% | 151.7% | 111.84% | 115.36% | 96.3% | 100.59% | - |
Selling, General & Admin | 28.7M | 18.12M | 37.21M | 35.87M | 39.13M | 33.84M | 38.13M | 40.63M |
SG&A % of Revenue | 109.6% | 96.12% | 154.39% | 125.1% | 114.84% | 90.7% | 91.43% | - |
Research & Development | 0 | 0 | 0 | 0 | 77K | 2.09M | 3.72M | 3.37M |
R&D % of Revenue | - | - | - | - | 0.23% | 5.6% | 8.92% | - |
Other Operating Expenses | 0 | 1.27M | -650K | -3.8M | 100K | 0 | 100K | 679K |
Operating Income | -14.92M▲ 0% | -9.61M▲ 35.6% | -25.2M▼ 162.3% | -18.58M▲ 26.3% | -22.68M▼ 22.0% | -17.21M▲ 24.1% | -9.15M▲ 46.8% | -8.92M▲ 0% |
Operating Margin % | -57% | -50.96% | -104.57% | -64.8% | -66.56% | -46.14% | -21.93% | -20.64% |
Operating Income Growth % | - | 35.63% | -162.35% | 26.27% | -22.04% | 24.11% | 46.84% | - |
EBITDA | -14.26M | -9.04M | -24.66M | -17.41M | -21.61M | -16.06M | -8.28M | -8.27M |
EBITDA Margin % | -54.45% | -47.98% | -102.33% | -60.71% | -63.44% | -43.06% | -19.85% | -19.14% |
EBITDA Growth % | - | 36.56% | -172.68% | 29.41% | -24.15% | 25.69% | 48.45% | 45.7% |
D&A (Non-Cash Add-back) | 667K | 562K | 540K | 1.17M | 1.06M | 1.15M | 868K | 649K |
EBIT | -8.79M | -8.03M | -37.3M | -238K | -19.52M | -15.63M | -9.15M | -8.92M |
Net Interest Income | -2.13M | -2.87M | -344K | -195K | -468K | -2.08M | -452K | -221K |
Interest Income | 25K | 28K | 16K | 175K | 132K | 30K | 0 | 0 |
Interest Expense | 2.16M | 2.9M | 360K | 370K | 600K | 2.11M | 452K | 221K |
Other Income/Expense | 3.97M | -1.32M | -12.46M | 17.97M | 2.56M | -527K | -1.36M | -2.14M |
Pretax Income | -10.95M▲ 0% | -10.92M▲ 0.2% | -37.66M▼ 244.7% | -608K▲ 98.4% | -20.12M▼ 3208.7% | -17.74M▲ 11.8% | -10.51M▲ 40.7% | -11.06M▲ 0% |
Pretax Margin % | -41.82% | -57.95% | -156.25% | -2.12% | -59.04% | -47.55% | -25.2% | -25.6% |
Income Tax | 33K | 64K | 56K | 32K | 14K | 22K | 25K | 27K |
Effective Tax Rate % | -0.3% | -0.59% | -0.15% | -5.26% | -0.07% | -0.12% | -0.24% | -0.24% |
Net Income | -10.98M▲ 0% | -10.99M▼ 0.0% | -37.71M▼ 243.3% | -640K▲ 98.3% | -20.13M▼ 3045.5% | -17.76M▲ 11.8% | -10.54M▲ 40.7% | -11.09M▲ 0% |
Net Margin % | -41.95% | -58.29% | -156.49% | -2.23% | -59.09% | -47.61% | -25.26% | -25.66% |
Net Income Growth % | - | -0.05% | -243.25% | 98.3% | -3045.47% | 11.78% | 40.67% | 3.82% |
Net Income (Continuing) | -10.98M | -10.99M | -37.71M | -640K | -20.13M | -17.76M | -10.54M | -11.09M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -18.09▲ 0% | -18.94▼ 4.7% | -44.10▼ 132.8% | -0.61▲ 98.6% | -13.02▼ 2034.4% | -3.22▲ 75.3% | -0.90▲ 72.0% | -0.95▲ 0% |
EPS Growth % | - | -4.7% | -132.84% | 98.62% | -2034.43% | 75.27% | 72.05% | 43.45% |
EPS (Basic) | -18.09 | -18.94 | -44.10 | -0.61 | -13.02 | -3.22 | -1.04 | - |
Diluted Shares Outstanding | 607K | 580K | 855.24K | 1.06M | 1.55M | 5.52M | 11.65M | 11.68M |
Basic Shares Outstanding | 607K | 580K | 855.24K | 1.06M | 1.55M | 5.52M | 10.17M | 11.68M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
BFRI Balance Sheet
Biofrontera Inc. (BFRI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 23.47M | 19.58M | 46.42M | 43.14M | 23.07M | 20.7M | 18.08M | 13.16M |
Cash & Short-Term Investments | 7.3M | 8.08M | 24.55M | 27.76M | 1.42M | 5.91M | 6.39M | 6.32M |
Cash Only | 7.3M | 8.08M | 24.55M | 17.21M | 1.34M | 5.91M | 6.39M | 6.32M |
Short-Term Investments | 0 | 0 | 0 | 10.55M | 78K | 7K | 9K | 0 |
Accounts Receivable | 4.79M | 3.29M | 3.78M | 7.41M | 5.16M | 5.32M | 7.29M | 3.88M |
Days Sales Outstanding | 66.72 | 63.69 | 57.31 | 94.27 | 55.3 | 52.01 | 63.81 | 38.27 |
Inventory | 10.48M | 7.09M | 4.46M | 7.17M | 10.91M | 6.65M | 1.43M | 1.23M |
Days Inventory Outstanding | 308.29 | 285.49 | 127.7 | 172.3 | 228.24 | 130.37 | 58.47 | 135.16 |
Other Current Assets | 186K | 619K | 12.81M | 286K | 5.28M | 2.83M | 2.97M | 1.73M |
Total Non-Current Assets | 5.28M | 4.56M | 6.8M | 7.74M | 4.86M | 1.4M | 10.48M | 11.63M |
Property, Plant & Equipment | 503K | 370K | 267K | 1.58M | 1.75M | 983K | 3.74M | 5.07M |
Fixed Asset Turnover | 52.05x | 50.94x | 90.26x | 18.16x | 19.51x | 37.95x | 11.15x | 17.13x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 4.29M | 3.87M | 3.45M | 3.03M | 2.63M | 35K | 2.65M | 2.61M |
Long-Term Investments | 0 | 0 | 2.81M | 0 | 0 | 0 | 200K | 200K |
Other Non-Current Assets | 494K | 323K | 3.08M | 3.13M | 482K | 383K | 3.89M | 3.95M |
Total Assets | 28.75M▲ 0% | 24.14M▼ 16.0% | 53.22M▲ 120.5% | 50.88M▼ 4.4% | 27.93M▼ 45.1% | 22.1M▼ 20.9% | 28.56M▲ 29.2% | 24.79M▲ 0% |
Asset Turnover | 0.91x | 0.78x | 0.45x | 0.56x | 1.22x | 1.69x | 1.46x | 1.94x |
Asset Growth % | - | -16.05% | 120.48% | -4.39% | -45.11% | -20.88% | 29.24% | 55.29% |
Total Current Liabilities | 11.74M | 4.42M | 13.84M | 20.89M | 18.09M | 12.02M | 11.89M | 10.92M |
Accounts Payable | 7.81M | 1.51M | 658K | 1.28M | 8.91M | 1.86M | 6.67M | 3.63M |
Days Payables Outstanding | 229.86 | 60.95 | 18.85 | 30.72 | 186.35 | 36.41 | 273.32 | 231.65 |
Short-Term Debt | 0 | 0 | 0 | 0 | 3.9M | 0 | 332K | 506K |
Deferred Revenue (Current) | 0 | 0 | 3.24M | 6.94M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.88M | 569K | 6.7M | 3.3M | 3.02M | 1.05M | 4.9M | 6.78M |
Current Ratio | 2.00x | 4.43x | 3.36x | 2.06x | 1.28x | 1.72x | 1.52x | 1.20x |
Quick Ratio | 1.11x | 2.82x | 3.03x | 1.72x | 0.67x | 1.17x | 1.40x | 1.09x |
Cash Conversion Cycle | 145.15 | 288.22 | 166.16 | 235.85 | 97.19 | 145.97 | -151.04 | -58.22 |
Total Non-Current Liabilities | 47.19M | 13.89M | 28.05M | 6.11M | 5.05M | 5.65M | 6.19M | 7.79M |
Long-Term Debt | 38.2M | 0 | 0 | 0 | 0 | 4.1M | 5.83M | 7.22M |
Capital Lease Obligations | 0 | 0 | 0 | 848K | 804K | 276K | 0 | 223K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 58K | 62K | 18.5M | 2.86M | 4.25M | 1.27M | 360K | 576K |
Total Liabilities | 58.93M | 18.31M | 41.88M | 27.01M | 23.14M | 17.67M | 18.08M | 18.72M |
Total Debt | 38.2M | 0 | 0 | 1.35M | 5.4M | 4.92M | 6.16M | 7.72M |
Net Debt | 30.9M | -8.08M | -24.55M | -15.86M | 4.06M | -983K | -231K | 1.41M |
Debt / Equity | - | - | - | 0.06x | 1.13x | 1.11x | 0.59x | 1.27x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.93x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.17x |
Interest Coverage | -4.07x | -2.77x | -103.60x | -0.64x | -32.53x | -7.42x | -20.24x | -40.36x |
Total Equity | -30.18M▲ 0% | 5.83M▲ 119.3% | 11.34M▲ 94.5% | 23.88M▲ 110.6% | 4.79M▼ 79.9% | 4.43M▼ 7.5% | 10.48M▲ 136.4% | 6.07M▲ 0% |
Equity Growth % | - | 119.31% | 94.54% | 110.6% | -79.93% | -7.51% | 136.41% | 1041.2% |
Book Value per Share | -49.72 | 10.05 | 13.26 | 22.59 | 3.10 | 0.80 | 0.90 | 0.52 |
Total Shareholders' Equity | -30.18M | 5.83M | 11.34M | 23.88M | 4.79M | 4.43M | 10.48M | 6.07M |
Common Stock | 0 | 8K | 17K | 1K | 2K | 9K | 12K | 12K |
Retained Earnings | -30.18M | -41.17M | -78.88M | -79.52M | -99.65M | -117.41M | -127.94M | -132.7M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BFRI Cash Flow Statement
Biofrontera Inc. (BFRI) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -37.68M | -12.37M | -26.71M | -16.2M | -24.89M | -10.27M | -13.36M | -9.31M |
Operating CF Margin % | -143.91% | -65.62% | -110.85% | -56.49% | -73.07% | -27.53% | -32.04% | - |
Operating CF Growth % | - | 67.17% | -115.98% | 39.36% | -53.68% | 58.75% | -30.1% | -216.31% |
Net Income | -10.98M | -10.99M | -37.71M | -640K | -20.13M | -17.76M | -10.54M | -11.09M |
Depreciation & Amortization | 667K | 562K | 540K | 1.17M | 1.06M | 1.15M | 138K | 122K |
Stock-Based Compensation | 0 | 0 | 129K | 1.85M | 1.04M | 1.02M | 951K | 712K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -3.42M | 883K | 11.83M | -21.37M | -2.48M | -891K | -430K | 720K |
Working Capital Changes | -23.94M | -2.83M | -1.5M | 2.79M | -4.39M | 6.21M | -3.48M | 217K |
Change in Receivables | -757K | 1.17M | -12M | 4.92M | 4.93M | -313K | -1.91M | 177K |
Change in Inventory | -3.54M | -273K | 2.59M | -2.81M | -3.75M | 4.23M | 1.45M | 1.63M |
Change in Payables | 1.44M | -3.4M | -773K | 0 | 6.42M | -1.81M | -535K | -1M |
Cash from Investing | 25.39M | 0 | -11K | -5.16M | 619K | -3K | 3M | 3M |
Capital Expenditures | -538K | 0 | -11K | -38K | -5K | -10K | -2K | -4K |
CapEx % of Revenue | 2.05% | - | 0.05% | 0.13% | 0.01% | 0.03% | 0% | 0.01% |
Acquisitions | 25.93M | 0 | 0 | 0 | 0 | 0 | 3M | 3M |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | -50K | 0 | 0 |
Cash from Financing | 16.4M | 13.19M | 43.19M | 14.02M | 8.41M | 14.84M | 10.85M | 10.85M |
Debt Issued (Net) | 13.5M | 8.79M | 0 | 0 | 3.9M | -265K | 10.85M | 10.85M |
Equity Issued (Net) | 0 | 0 | 29.94M | 9.39M | 4.51M | 7.66M | 10.85M | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 2.9M | 4.4M | 13.25M | 4.63M | 0 | 7.44M | -10.85M | 0 |
Net Change in Cash | 4.12M▲ 0% | 825K▼ 80.0% | 16.46M▲ 1895.8% | -7.33M▼ 144.5% | -15.87M▼ 116.3% | 4.56M▲ 128.8% | 487K▼ 89.3% | 4.53M▲ 0% |
Free Cash Flow | -38.22M▲ 0% | -12.37M▲ 67.6% | -26.73M▼ 116.1% | -16.24M▲ 39.2% | -24.9M▼ 53.4% | -10.33M▲ 58.5% | -13.36M▼ 29.4% | -9.32M▲ 0% |
FCF Margin % | -145.96% | -65.62% | -110.9% | -56.63% | -73.08% | -27.69% | -32.04% | -21.57% |
FCF Growth % | - | 67.63% | -116.07% | 39.25% | -53.35% | 58.51% | -29.36% | 15.81% |
FCF per Share | -62.96 | -21.33 | -31.25 | -15.36 | -16.10 | -1.87 | -1.15 | -0.80 |
FCF Conversion (FCF/Net Income) | 3.43x | 1.13x | 0.71x | 25.31x | 1.24x | 0.58x | 1.27x | 0.84x |
Interest Paid | 1.71M | 3.07M | 2K | 1K | 147K | 1.73M | 0 | 3K |
Taxes Paid | 50K | 64K | 56K | 32K | 15K | 24K | 0 | 0 |
BFRI Key Ratios
Biofrontera Inc. (BFRI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -188.52% | -439.39% | -3.63% | -140.43% | -384.98% | -141.3% | -476.72% |
Return on Invested Capital (ROIC) | - | - | -173.85% | -201.69% | -209.9% | -100.17% | -274.99% |
Gross Margin | 51.9% | 47.13% | 47.04% | 48.8% | 50.12% | 78.65% | 82.79% |
Net Margin | -58.29% | -156.49% | -2.23% | -59.09% | -47.61% | -25.26% | -25.66% |
Debt / Equity | - | - | 0.06x | 1.13x | 1.11x | 0.59x | 1.27x |
Interest Coverage | -2.77x | -103.60x | -0.64x | -32.53x | -7.42x | -20.24x | -40.36x |
FCF Conversion | 1.13x | 0.71x | 25.31x | 1.24x | 0.58x | 1.27x | 0.84x |
Revenue Growth | -28.01% | 27.86% | 18.98% | 18.82% | 9.49% | 11.8% | 13.7% |
Related:BFRI Dividend History·BFRI Revenue History·BFRI Price History·BFRI P/E History·BFRI Financial Ratios·BFRI Institutional Holders
BFRI SEC Filings & Documents
Biofrontera Inc. (BFRI) SEC filings — annual & quarterly reports (10-K, 10-Q)
BFRI Frequently Asked Questions
Biofrontera Inc. (BFRI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Biofrontera Inc. (BFRI) reported $43.2M in revenue for fiscal year 2025. This represents a 65% increase from $26.2M in 2019.
Biofrontera Inc. (BFRI) grew revenue by 11.8% over the past year. This is steady growth.
Biofrontera Inc. (BFRI) reported a net loss of $11.1M for fiscal year 2025.
Dividend & Returns
Biofrontera Inc. (BFRI) has a return on equity (ROE) of -141.3%. Negative ROE indicates the company is unprofitable.
Biofrontera Inc. (BFRI) had negative free cash flow of $9.3M in fiscal year 2025, likely due to heavy capital investments.